Navigation Links
Avastin, anti-Cancer Drug leads to Blindness and Other Complications

Researchers at the Genentech Inc.'s said that Avastin, a cancer drug may cause trigger a rare brain condition, reversible posterior leukoencephalopathy syndrome//. This was published in the New England Journal of Medicine.

It was found that two female cancer patients in their 50s treated with Avastin developed reversible posterior leukoencephalopathy syndrome (RPLS). This condition leads to blindness and other complications. Doctors said that both the patients have recovered.

Hal Barron, Genentech's chief medical officer said that his company is investigating a possible third case and is undertaking a review to see whether other patients have signs of the condition. The company also said that it will revise prescription information on the drug, which had $1.13 billion in sales last year.

Avastin is the first drug approved to fight cancer by choking off the blood supply that feeds the tumors. Parameswaran Hari, an assistant professor and oncologist at the Medical College of Wisconsin, in Milwaukee, who treated one of the patients, said that doctors should keep close watch for the syndrome in patients whose blood pressure rises during treatment with Avastin.

This results in the lesion formation in the brain which resembles a stroke leading to permanent vision loss and other complications if not treated immediately. This dangerous brain condition has been previously linked to treatment with chemotherapy and immune-suppressing drugs.


'"/>




Page: 1

Related medicine news :

1. Drinking arsenic water leads to cancer
2. Coronary stent leads to complications
3. Starving leads to obesity
4. Drug abuse leads to long standing changes in the brain
5. Deprived sleep leads to ageing
6. Tobacco chewing leads to dental caries
7. Tongue piercing leads to bacterial infection
8. Cathine leads to mental health disorder
9. Space research leads to needle-free blood tests
10. Canada stunned as mad cow discovery leads to beef ban
11. Doctor Pleads Not Guilty
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd ... at 10 North Broadway Avenue, will be an educational and exciting program providing ... in the management of chronic pain. , Oklahoma is in a healthcare crisis. ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The TouchPoint Solution, ... the world to manage stress and anxiety. , “Buzzies change the way we ... and co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and ... and Director, AMN Healthcare: Susan Salka , 43rd President of the United States ... Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! Time to ... summer internships , which can be frustrating when they don’t even know how ... Group, a boutique public relations firm outside of Philadelphia, have offered these three tips ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... significant unmet medical needs in rare diseases, today announced ... webcast on Monday, April 3 during ENDO 2017, the ... Orlando, Florida , to discuss new data regarding ... TransCon PTH and TransCon CNP). Ascendis is ...
(Date:3/23/2017)... , March 23, 2017  A new ... and accurate identification of individuals who carry ... for a rare yet potentially deadly side effect ... bipolar disorder.  The gene HLA-B*15:02 is ... such as Stevens-Johnson syndrome and toxic epidermal necrolysis ...
(Date:3/23/2017)... , March 23, 2017 ... from the TACTI-mel trial of IMP321 in combination with ... the first (1mg/kg) cohort experiencing a complete response. Recruitment ... cohort is expected to be fully recruited by Q317. ... the AIPAC breast cancer study are expected mid-year (recruitment ...
Breaking Medicine Technology: